PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback